Results 81 to 90 of about 18,119,282 (331)

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Therapies for Advanced Parkinson’s Disease in Sweden: A Cost-Effectiveness Analysis Using Real-World Data

Neurology and Therapy
Introduction The Swedish Parkinson’s Disease (PD) Registry provides rich data on cost and quality of life for patients receiving device-aided therapies (DATs) for Parkinson’s disease in Sweden.
Dag Nyholm, Simon Eggington, Astrid Holm
doaj   +1 more source

Quality of life burden on United States infants and caregivers due to lower respiratory tract infection and adjusting for selective testing: Pilot prospective observational study

Health Science Reports, 2023
Background and Aims Policymakers need data about the burden of respiratory syncytial virus (RSV) lower respiratory tract infections (LRTI) among infants.
Dhwani Hariharan, V. S. Senthil Kumar, Elizabeth L Glaser, William H. Crown, Zachary A. Wolf, Kimberley A. Fisher, Charles T. Wood, William F. Malcolm, Christopher B. Nelson, Donald S. Shepard   +9 more
doaj   +1 more source

Summarized results of willingness to pay per quality-adjusted life year in 64 studies.

Summarized results of willingness to pay per quality-adjusted life year in 64 studies.
Klas Göran Sahlen (17935584), Lars Lindholm (21685), Anh Nu Vu (17935581), Minh Van Hoang (6842081), Cuc Thi Thu Nguyen (14059662), Sun Sun (15469762)   +5 more
core   +1 more source

Summary of disability-adjusted life year calculation methods for brucellosis.

, 2022
Summary of disability-adjusted life year calculation methods for brucellosis.
David M. Pigott (8067494), Ben Huntington (14253576), Brecht Devleesschauwer (505283), Narmada Venkateswaran (14253573), Grace T. Patterson (12174272), Mieghan Bruce (4924051), Paul Torgerson (505285), Carlotta Di Bari (13007651), Christina Fastl (9473503), Jonathan Rushton (503844)   +9 more
core   +1 more source

Productivity and quality-adjusted life years: QALYs, PALYs and beyond

, 2023
We develop a unified framework for the measurement and valuation of health and productivity. Within this framework, we characterize evaluation functions allowing for compromises between the classical quality-adjusted life years (QALYs) and its polar productivity-adjusted life years (PALYs).
Schultz Hansen, Kristian, Moreno-Ternero, Juan D., Østerdal, Lars Peter   +2 more
openaire   +3 more sources

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach, Gizem Abaci, Tom Huberty, Axel Lechner, Lukas Käsmann, Jens Ricke, Sophia Stöcklein, Martin Canis, Philipp Baumeister, Marianna Alunni‐Fabbroni   +9 more
wiley   +1 more source

Cost effectiveness of bevacizumab plus carboplatin paclitaxel versus carboplatin paclitaxel as front line for advanced ovarian cancer in Thailand

Scientific Reports
Bevacizumab (BEV) combined with standard chemotherapy with carboplatin and paclitaxel (CP) as the front-line treatment for newly diagnosed advanced-stage epithelial ovarian cancer (EOC) is a promising treatment option.
Kanyarat Katanyoo, Usa Chaikledkaew, Nutthaporn Chandeying   +2 more
doaj   +1 more source

Justifying Terminal Care by 'Retrospective Quality-Adjusted Life-Years'

, 2010
A lot of medical procedures can be justified in terms of the number of quality-adjusted life-years (QALYs) they can be expected to generate; that is, the number of extra years that the procedure will provide, with the quality of life during those extra ...
Cowley, Christopher
core   +1 more source